Track Enlivex Therapeutics Ltd. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Enlivex Therapeutics Ltd. ENLV · Stock Open Enlivex Therapeutics Ltd. in new tab

1.19 USD
P/E
0.00
EPS
7904.00
P/B
0.00
ROE
162.86
Beta
1.61
Loading chart...
Key Metrics
Earnings dateNov. 13, 2026
P/E0.00
EPS7904.00
Book Value3705.55
Price to Book0.00
Debt/Equity0.45
% Insiders55.898%
Estimates
Forward P/E-1.76
Forward EPS-0.78

DCF valuation

Model fair value for Enlivex Therapeutics Ltd. (ENLV)
Result
Sign in to run the valuation for ENLV.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Enlivex Therapeutics Ltd. Logo Enlivex Therapeutics Ltd. Analysis (ENLV)

Israel Health Care Official Website Stock

Is Enlivex Therapeutics Ltd. a good investment? Enlivex Therapeutics Ltd. (ENLV) is currently trading at 1.19 USD.

In terms of valuation, the stock trades at a P/E ratio of 0.00. This relatively low multiple may signal that Enlivex Therapeutics Ltd. is undervalued compared to historical market norms.

Earnings Schedule: Enlivex Therapeutics Ltd. is expected to release its next earnings report on Nov. 13, 2026. The market consensus estimate for Forward EPS is -0.78.

Investor FAQ

Does Enlivex Therapeutics Ltd. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Enlivex Therapeutics Ltd.?

Enlivex Therapeutics Ltd. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Nov. 13, 2026. The company currently has a trailing EPS of 7904.00.

Company Profile

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.

Exchange Ticker
FRA (Germany) 1BT.F
STU (Germany) 1BT.SG
NMS (United States) ENLV
TLV (Israel) ENLV.TA
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Sept. 25, 2017 1:5
March 6, 2019 1:8
July 9, 2026 Needs review
Oct. 27, 2026 1:16
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion